Bio-Rad Laboratories, Inc. experienced a contracting week.
Principal Securities Inc. acquired new holdings, while
Westfield Capital Management Co. LP sold 115,118 shares and the
Bio-Rad stock declined by 14%. Despite a three-year performance that left initial investors at a loss, the outlook remains moderately positive, with some entities like
ING Groep NV and
Yousif Capital Management LLC increasing their stock positions. The company's Q1 2024 earnings have surpassed estimates, but revenues fell short. Despite the soft BioPharma market and stiff competition causing discomfort, several brokerages have given the company a “Moderate Buy” rating. In terms of financial health, the firm boasts a strong balance sheet, though Analysts have forecasted mixed prospects for the stock.
Bio-Rad Laboratories announced a new EVP, CFO, and a $500M share repurchase program, providing some indication for future stability.
Bio-Rad Laboratories Stocks News Analytics from Sun, 07 Jun 2015 03:49:27 GMT to Sun, 26 May 2024 20:32:43 GMT -
Rating -3
- Innovation 2
- Information 8
- Rumor -4
